過去1週間は、この産業の総時価総額が2021年7月以来初めて12兆ドルを下回った暗い期間でした。この混乱の大部分は、リアルタイムで崩壊することによって引き起こされたものです。 $Terra(LUNA.CC)$.
先週、Terraはネイティブトークンが$0.0003、ほぼゼロに達すると、ブロックの生成を正式に停止しました。
多額のスタート...

2022年1月3日月曜日
ジミーによる
$ヌーホールディングス(NU.US)$ $ペイパル ホールディングス(PYPL.US)$ $シー(SE.US)$ $ユナイテッド エアラインズ ホールディングス(UAL.US)$

Q&A is a session under a company's earnings conference that institutional and retail investors ask some most-concerned questions to the management. On this page, you may discover info that might affect the stock price in the following weeks. $モデルナ(MRNA.US)$
Key Takeaways:
Attitudes: some Q4 deliveries may still move to early 2022. In 2022 there might be a large volume, but way lower than what the commercial market could drive.
Goals: expect to deliver 700 to 800 million doses in 2021. This compares to the prior outlook of 800 million to 1 billion doses.
For 2022, can you walk through the supply aspects. Are you still guiding to up to 3 billion doses here?
Yes, we could see make up to 3 billion doses in terms of material. As you know, that number was really depending on the booster dose. And now that we're on the other side of that decision with the 50-microgram dose, we confirmed we could make up to 3 billion doses, if there was a need for it. The challenge in 2022 is going to really be around product form because as the market moves to an endemic market, you're going to need basically vials to be able to go to less number of dose per vile.
You lowered 2021 a little bit, I think, by 5 billion, but raised 2022, 2022 by 5 billion. Is that a timing shift of deliveries? And how much of that is just option contracts as you think about 2022?
On '21, so there's two things I think that is driving, first is, of course the lower volume. And the second one is price. As you know, we are working very hard with several governments to send products that they have bought for high-income countries like the U.S. to low-income country this side of Christmas. When we announced our African Union partnership, the U.S. decided to delay to Q2, the delivery over December quarter. That volume is going to African Union at a low tier price. And some orders that are moving from December to January on the supply volume side of things.
Given your comments on the call about potentially moving into the endemic phase by the second half of next year. Should we think about 2022 revenue as being weighted toward the first half of the year?
On the endemic and the ventilation of the sales over the year, I think it will be dangerous to assume at this stage one way or other in terms of first half and second half because of volume and also pricing. As you get a sense, the COVAX, the African Union and some BARDA deals we have are lower prices. And so there might be a large volume, but probably way lower than what the commercial market could drive, which we believe is going to be above what has been the pandemic price again because of volume. I would be cautioned that assuming Q1 to be lower and Q2 is a bit too early.
Just curious on the guidance for the 2 billion guidance for the U.S. fall 2022 booster market. Can you help us understand what assumptions are sort of built into that number?
So on the fall of '22, so the commercial team has spent quite a lot of time modeling different assumptions in terms of volume of people who want the boost, market share, and, of course, pricing. I cannot comment further for competitive reason right now, especially on the pricing piece, but we will do that in due time. But indeed it's typical commercial analysis that the team that has done many times before in other companies have run through the last few months.
How much perspective can you give us on you're able to potentially compete for share on contracting in EU, the competitor Pfizer/BioNTech locked in pretty large contracts on volume for the next two years?
The other vaccines that other than mRNA, I'm not sure, used anymore as my understanding, they're mostly given through COVAX. I think we have an interesting opportunity because as I shared you talk to healthcare leaders, health minister, as you get more and more data that Paul shared, we have a better and better understanding that the two mRNA vaccines are not the same. And so again, as we look into 2022, we already have a contract with Europe in '22. And we are discussing also with country by country on the data and using the benefit of the Moderna vaccine versus the other one.
This article is a script from the Q&A session of MRNA earnings call on Nov 2. In order to facilitate reading, we have made appropriate cuts. If you want to know more details, you can click here for details.

主要な投資プラットフォームやソーシャルメディアからのトップトレンド株のコレクション、Top 5 stocks from different platformsは、投資家に場所を越えたトレンド株のリストを提供します。
Moomooは、RobinhoodとInvesting.comから最も人気の高い株、Yahoo Finance、Stocktwits、そしてmoomooから最も活発な株を選びます。
- $エヌビディア(NVDA.US)$株価が年初来120%近くまで上昇する中、Nvidia Corp.は木曜日に高値を更新し、レコードを更新しました。2021年に株式が倍以上になった同社の例に続く形で株価が上昇しました。
詳しくはこちらをご覧ください：Nvidia hits record high as stock surge nears 120% this year.
- $ウーバー テクノロジーズ(UBER.US)$株価は本来のセッションで1%下落し、アフターセッションで2%以上下落した後、5:30 pm時点でわずかに上昇しています。同社は、売上高が前年比で57%増加し、23.1 billionドルに達したが、アナリストの予想の23.3 billionドルに及ばなかったことを明らかにしました。また、トリップ数も前年比で39%増加し、1.64 billionになりましたが、アナリストの1.69 billionには届きませんでした。コロナウイルスの影響を受けたドライバー供給は前年比で60%増加しました。
詳しくはこちらをご覧ください：Uber revenue rises across ride-hailing and delivery, but losses also increase.
- $AMCエンターテインメント HD A(AMC.US)$映画館企業は、米国のショッピングモールでアメリカン・マルチシネマ（AMC）のポップコーン店、カウンター、キオスクを最大5店舗立ち上げ、2022年上半期には15店舗を開業する計画だ。会社は新型コロナウイルス感染拡大の影響を受け、収益を多様化することを目指してきたことから、同CEO Adam Aronはこの動きを「自然で論理的な」ものと位置付けました。
詳しくはこちらをご覧ください：AMC to sell its own branded popcorn at mall kiosks, supermarkets in 2022。

こんにちはmooerたち、今週の収益をフォローしていますか？　私たちのチャレンジ株式チャートによる、再開です! 今すぐ確認して参加して報酬を獲得しよう！:
チャレンジ：以下のチャートを見て、対応する株の名前を教えてください。（例：Tesla、Apple、AMC）
ルール：最初のそして、最後のmooerたちが、この投稿の有効期間内に正しい答えを出した場合、獲得者となります！報酬：2人のラッキーな勝者は、それぞれ800ポイントの報酬を獲得することができます！
800ポイントずつ！
有効期間：この投稿の有効期間内にコメントで回答をお書きください。2021年11月08日11:59AM ETまでに回答してください。/2021年11月09日 12:59 AM SGT.
今すぐコメントして勝利しよう！
ヒント：決算発表がどのように株価に影響するか？
図表1：
キーワード - COVIDワクチン
図表2：
キーワード - 販売予測の下方修正
図表3：
キーワード - ライドヘイリング

$ブラックロック A(BLK.US)$ロック？ロック